{
    "2019-03-19": [
        [
            {
                "time": "",
                "original_text": "凯莱英：紧锣密鼓布局大分子产品线 增持评级",
                "features": {
                    "keywords": [
                        "凯莱英",
                        "大分子产品线",
                        "增持评级"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2023-03-19",
                "original_text": "券商首次关注8股并给予买入评级（3月19日）",
                "features": {
                    "keywords": [
                        "券商",
                        "买入评级"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "【国金研究】凯莱英18年业绩点评：年报符合预期，先进制造+中国医药创新优质标的保持稳健高增长",
                "features": {
                    "keywords": [
                        "凯莱英",
                        "18年业绩",
                        "年报",
                        "先进制造",
                        "医药创新",
                        "稳健高增长"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "凯莱英去年净利4.28亿元增长25% 董事长HAO HONG年薪为308万元",
                "features": {
                    "keywords": [
                        "凯莱英",
                        "净利",
                        "增长25%",
                        "董事长",
                        "年薪"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}